Prof. PeptideProf. Peptide

November 6, 2026

Orthopaedic Journal JAAOS Reviews BPC-157, Thymosin Beta-4 and TB-500: No Controlled Orthopaedic Evidence

On October 27, 2026, the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) published a review of BPC-157, thymosin beta-4 and TB-500 written for orthopaedic clinicians. Its authors, Tham, Hodgkins and Kennedy, found that none of the three has “an FDA-approved musculoskeletal indication, validated orthopaedic treatment protocol, or controlled human orthopaedic efficacy evidence,” and concluded that “routine clinical use cannot be currently recommended.”

A narrative review, not a trial. The paper tests none of the compounds. It summarizes published studies and regulatory sources and gives the authors’ reading of them. Everything below is from its abstract, quoted or paraphrased; the full text was not read for this article.

What the review is

The authors searched PubMed/MEDLINE, EMBASE and Scopus from inception through June 2026, and also reviewed primary regulatory and anti-doping sources. They covered each compound’s molecular rationale, its direct musculoskeletal evidence, human safety and efficacy data, product quality, regulatory status, anti-doping rules, and what all of that means for counselling patients. The review describes these products as “increasingly promoted for musculoskeletal recovery despite limited clinical validation.”

BPC-157

The review finds that BPC-157 has the largest body of direct musculoskeletal preclinical evidence of the three, mostly small-animal studies of tendon, ligament, muscle, inflammatory joint disease and bone. In people, it says, “human musculoskeletal evidence is limited to one small retrospective uncontrolled case series without validated outcome measures,” and “validated dosing, pharmacokinetic, and long-term safety data are lacking.” What clinics and the few human studies report on BPC-157 doses is collected in How Is BPC-157 Dosed?

That matches the systematic review in Acta Orthopaedica Belgica published three weeks earlier. That review found three human studies of BPC-157 in any use, 30 participants in total, and rated the certainty of the evidence very low. The two papers differ in design: the Acta review is a registered systematic review of one compound’s human evidence, and the JAAOS review is a narrative review of three compounds, written for counselling.

Thymosin beta-4

According to the review, thymosin beta-4 has broader experimental and human experience than BPC-157, in eye, skin and cardiovascular uses. Its direct musculoskeletal evidence, however, “remains limited to in vitro and rodent studies,” and the authors write that the findings outside orthopaedics “cannot establish musculoskeletal efficacy or safety.”

TB-500 is not thymosin beta-4

The review draws a line that much of the market blurs. It describes TB-500 as “a distinct seven amino-acid fragment of TB-4 that is frequently conflated with full-length TB-4 despite the absence of validated biologic or clinical equivalence.” On the review’s reading, the human experience with thymosin beta-4 does not carry over to products sold as TB-500.

Products, regulation and anti-doping

The authors write that commercial products raise concerns about “identity, purity, concentration, sterility, and manufacturing consistency.” None of the three compounds has an FDA-approved musculoskeletal indication. The abstract also flags anti-doping restrictions for athletes; it does not list the specific rules.

What it tells clinicians

The review’s advice is addressed to the profession. It says orthopaedic clinicians “should specifically ask about peptide use, distinguish preclinical plausibility from clinical validation, address product quality and safety uncertainties, and counsel athletes regarding antidoping restrictions.” Its conclusion is that routine clinical use cannot currently be recommended. The regulatory background, including the HHS policy on 503A compounding of BPC-157 and TB-500 published three days later, is in HHS Will Not Act Against 503A Pharmacies Compounding Six Peptides.

What this is, and isn’t

This is a report on a published narrative review, read from its abstract. It is not an evaluation of any product or seller, and it does not say that any of the three compounds works or is safe or unsafe in people. None of them is approved for human use. Nothing here is medical advice, a dosing recommendation or a usage recommendation.

Sources

This article is for informational and educational purposes only and does not constitute medical advice. It reports the conclusions of a published narrative review from its abstract; it makes no safety, efficacy, dosing, or approval claim about any compound. BPC-157, thymosin beta-4 and TB-500 are unapproved research compounds. All research compounds referenced are for laboratory use only and are not for human consumption.

Checked and updated